TY - JOUR
T1 - EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
T2 - 2023 update
AU - Moseng, Tuva
AU - Vliet Vlieland, Theodora P.M.
AU - Battista, Simone
AU - Beckwée, David
AU - Boyadzhieva, Vladimira
AU - Conaghan, Philip G.
AU - Costa, Daniela
AU - Doherty, Michael
AU - Finney, Andrew G.
AU - Georgiev, Tsvetoslav
AU - Gobbo, Milena
AU - Kennedy, Norelee
AU - Kjeken, Ingvild
AU - Kroon, Féline P.B.
AU - Stefan Lohmander, L.
AU - Lund, Hans
AU - Mallen, Christian D.
AU - Pavelka, Karel
AU - Pitsillidou, Irene A.
AU - Rayman, Margaret P.
AU - Tveter, Anne Therese
AU - Vriezekolk, Johanna E.
AU - Wiek, Dieter
AU - Zanoli, Gustavo
AU - Østerås, Nina
N1 - Publisher Copyright:
© European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by BMJ on behalf of EULAR.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and improve function and quality of life. EULAR recommendations for the non-pharmacological core management of hip and knee OA were published in 2013. Given the large number of subsequent studies, an update is needed. Methods The Standardised Operating Procedures for EULAR recommendations were followed. A multidisciplinary Task Force with 25 members representing 14 European countries was established. The Task Force agreed on an updated search strategy of 11 research questions. The systematic literature review encompassed dates from 1 January 2012 to 27 May 2022. Retrieved evidence was discussed, updated recommendations were formulated, and research and educational agendas were developed. Results The revised recommendations include two overarching principles and eight evidence-based recommendations including (1) an individualised, multicomponent management plan; (2) information, education and self-management; (3) exercise with adequate tailoring of dosage and progression; (4) mode of exercise delivery; (5) maintenance of healthy weight and weight loss; (6) footwear, walking aids and assistive devices; (7) work-related advice and (8) behaviour change techniques to improve lifestyle. The mean level of agreement on the recommendations ranged between 9.2 and 9.8 (0–10 scale, 10=total agreement). The research agenda highlighted areas related to these interventions including adherence, uptake and impact on work. Conclusions The 2023 updated recommendations were formulated based on research evidence and expert opinion to guide the optimal management of hip and knee OA.
AB - Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and improve function and quality of life. EULAR recommendations for the non-pharmacological core management of hip and knee OA were published in 2013. Given the large number of subsequent studies, an update is needed. Methods The Standardised Operating Procedures for EULAR recommendations were followed. A multidisciplinary Task Force with 25 members representing 14 European countries was established. The Task Force agreed on an updated search strategy of 11 research questions. The systematic literature review encompassed dates from 1 January 2012 to 27 May 2022. Retrieved evidence was discussed, updated recommendations were formulated, and research and educational agendas were developed. Results The revised recommendations include two overarching principles and eight evidence-based recommendations including (1) an individualised, multicomponent management plan; (2) information, education and self-management; (3) exercise with adequate tailoring of dosage and progression; (4) mode of exercise delivery; (5) maintenance of healthy weight and weight loss; (6) footwear, walking aids and assistive devices; (7) work-related advice and (8) behaviour change techniques to improve lifestyle. The mean level of agreement on the recommendations ranged between 9.2 and 9.8 (0–10 scale, 10=total agreement). The research agenda highlighted areas related to these interventions including adherence, uptake and impact on work. Conclusions The 2023 updated recommendations were formulated based on research evidence and expert opinion to guide the optimal management of hip and knee OA.
KW - Osteoarthritis
KW - Osteoarthritis, Knee
KW - Physical Therapy Modalities
KW - Rehabilitation
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85183295213&partnerID=8YFLogxK
U2 - 10.1136/ard-2023-225041
DO - 10.1136/ard-2023-225041
M3 - Article
C2 - 38212040
AN - SCOPUS:85183295213
SN - 0003-4967
VL - 83
SP - 730
EP - 740
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 6
M1 - 224997
ER -